Prinicple Investigator of Suspended Cytori Stem Cell Trials Remains Hopeful

August 7, 2014

(Forbes) – Shares of Cytori Therapeutics took a big bit hit today after the company disclosed in a press release that it had suspended enrollment in its ATHENA and ATHENA II trials. This kind of news is never a good sign, but the   principal investigator of the trial tells me that he believes the current problems are surmountable and that the trials are still viable. The twin trials are each testing Cytori’s adipose-derived regenerative cells (ADRC) against placebo in 45 patients with advanced heart disease who are not eligible for bypass surgery or stents.